Don’t miss the latest developments in business and finance.

Covid: Covishield price for states reduced by 25% to Rs 300 per dose

SII's CEO Adar Poonawalla took to Twitter to announce the 'philanthropic' gesture

Covishield
Covishield (Photo: Reuters)
Press Trust of India New Delhi
3 min read Last Updated : Apr 28 2021 | 7:23 PM IST
Serum Institute of India (SII) -- the maker of the most used COVID-19 vaccine in the country -- on Wednesday announced a cut in price of the jab it plans to sell to states to Rs 300 per dose from the earlier Rs 400.

This follows widespread criticism of its pricing policy as it has sold the initial doses of Covishield to the central government at Rs 150 per dose.

SII's CEO Adar Poonawalla took to Twitter to announce the "philanthropic" gesture.

"As a philanthropic gesture on behalf of @SerumInstIndia, I hereby reduce the price to the states from Rs 400 to Rs 300 per dose, effective immediately; this will save thousands of crores of state funds going forward. This will enable more vaccinations and save countless lives," he said.

According to official sources, the central government on Monday had asked SII and Bharat Biotech to lower the prices of their COVID-19 vaccines amid criticism from various states who accused the companies of profiteering during such a major crisis.

The issue of vaccine pricing was discussed at a meeting chaired by Cabinet Secretary Rajiv Gauba.

Also Read


Many states have objected to the different prices for the vaccines.

Last week, SII had defended the pricing of the Covishield vaccine, saying the earlier price was based on advance funding and now it has to invest in scaling up and expanding capacity to produce more shots.

The company, which manufactures the Oxford-AstraZeneca vaccine at Pune, had on April 21 announced a price of Rs 600 per dose for private hospitals and at Rs 400 for state governments and for any new contract by the central government.

"The current situation is extremely dire, the virus is constantly mutating while the public remains at risk. Identifying the uncertainty, we have to ensure sustainability as we must be able to invest in scaling up and expanding our capacity to fight the pandemic and save lives," the company had earlier said.

The government last week waived basic customs duty on import of COVID vaccines, medical grade oxygen and related equipment for three months.

India has announced expansion of its COVID-19 vaccination drive by allowing its large 18-plus population to get inoculated from May 1.

Meanwhile, Congress leader Rahul Gandhi on Wednesday hit out at the government over the "high" COVID vaccine prices, saying the system has once again failed Indian citizens.

"People's money was given to vaccine companies to develop COVID vaccines. Now, GOI will make the same people pay the highest price in the world for these vaccines," he alleged on Twitter.

"Once again, the failed 'system' fails our citizens for Modi-mitrs' profit," he said.

Congress leader Jairam Ramesh also lamented that only 2.36 crore people have been fully vaccinated in the country.

"In January 2021, the Modi government set a target of vaccinating 30 crore Indians by August 2021. While 12.12 crore have received 1 dose of vaccine, ONLY 2.36 crore are FULLY vaccinated. That's around 8 percent.

"Increasing vaccine supply and rate of vaccination must be of HIGHEST priority, and is a huge collective enterprise," Ramesh said on Twitter.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

More From This Section

Topics :CoronavirusSerum Institute of India

First Published: Apr 28 2021 | 6:29 PM IST

Next Story